NASDAQ:MGEN Miragen Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Miragen Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.80 +0.00 (+0.26 %) (As of 09/30/2020 10:30 AM ET) Add Compare Share Today's Range$0.79Now: $0.80▼$0.8450-Day Range$0.73MA: $0.95▼$1.1652-Week Range$0.31Now: $0.80▼$2.27Volume6,227 shsAverage Volume2.26 million shsMarket Capitalization$45.30 millionP/E RatioN/ADividend YieldN/ABeta2.14 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous, ocular, and idiopathic pulmonary fibrosis; and MRG-110, an inhibitor of miR-92, a microRNA expressed in endothelial cells for the treatment of heart failure, as well as surgical incisions in high risk populations, severe lacerations, and severe burns in the United States and Japan. The company has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Servier for the development of MRG-110. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingMiragen Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, Miragen Therapeutics has a forecasted upside of 526.5% from its current price of $0.80.Amount of Analyst CoverageMiragen Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesMiragen Therapeutics has received 260 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMiragen Therapeutics has received 221 “underperform” votes. (Add your “underperform” vote.)Community SentimentMiragen Therapeutics has received 54.05% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Miragen Therapeutics and other stocks. Vote “Outperform” if you believe MGEN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MGEN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMiragen Therapeutics does not currently pay a dividend.Dividend GrowthMiragen Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Miragen Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.00% of the stock of Miragen Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 19.01% of the stock of Miragen Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Miragen Therapeutics are expected to grow in the coming year, from ($0.55) to ($0.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Miragen Therapeutics is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Miragen Therapeutics is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMiragen Therapeutics has a P/B Ratio of 1.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.35 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MGEN Previous Symbol CUSIPN/A CIK1590750 Webwww.signalgenetics.com Phone720-643-5200Debt Debt-to-Equity Ratio0.25 Current Ratio4.84 Quick Ratio4.84Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$4.46 million Price / Sales10.16 Cash FlowN/A Price / Cash FlowN/A Book Value$0.45 per share Price / Book1.78Profitability EPS (Most Recent Fiscal Year)($1.34) Net Income$-41,870,000.00 Net Margins-1,393.50% Return on Equity-164.54% Return on Assets-101.20%Miscellaneous Employees77 Outstanding Shares56,610,000Market Cap$45.30 million Next Earnings Date11/5/2020 (Estimated) OptionableNot Optionable $0.80 +0.00 (+0.26 %) (As of 09/30/2020 10:30 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive MGEN News and Ratings via Email Sign-up to receive the latest news and ratings for MGEN and its competitors with MarketBeat's FREE daily newsletter. Miragen Therapeutics (NASDAQ:MGEN) Frequently Asked Questions How has Miragen Therapeutics' stock been impacted by Coronavirus (COVID-19)? Miragen Therapeutics' stock was trading at $0.6119 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MGEN shares have increased by 35.6% and is now trading at $0.83. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Miragen Therapeutics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Miragen Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Miragen Therapeutics. When is Miragen Therapeutics' next earnings date? Miragen Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for Miragen Therapeutics. How were Miragen Therapeutics' earnings last quarter? Miragen Therapeutics Inc (NASDAQ:MGEN) posted its earnings results on Wednesday, August, 5th. The medical research company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.05. The medical research company earned $0.17 million during the quarter, compared to the consensus estimate of $0.65 million. Miragen Therapeutics had a negative net margin of 1,393.50% and a negative return on equity of 164.54%. View Miragen Therapeutics' earnings history. What price target have analysts set for MGEN? 5 brokerages have issued 1 year target prices for Miragen Therapeutics' shares. Their forecasts range from $3.00 to $6.00. On average, they anticipate Miragen Therapeutics' share price to reach $5.00 in the next year. This suggests a possible upside of 502.4% from the stock's current price. View analysts' price targets for Miragen Therapeutics. Who are some of Miragen Therapeutics' key competitors? Some companies that are related to Miragen Therapeutics include Enzo Biochem (ENZ), Celcuity (CELC), Biocept (BIOC), Anpac Bio-Medical Science (ANPC), OpGen (OPGN), Psychemedics (PMD), American Shared Hospital Services (AMS), American Shared Hospital Services (AMS), Avant Diagnostics (AVDX), PotNetwork (POTN), CBA Florida (CBAI), Cancer Genetics (CGIX), First Choice Healthcare Solutions (FCHS), Aeon Global Health (AGHC) and ACI Global (ACGJ). View all competitors. What other stocks do shareholders of Miragen Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Miragen Therapeutics investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), KushCo (KSHB), Zosano Pharma (ZSAN), BioNano Genomics (BNGO), Gran Tierra Energy (GTE), Pennsylvania R.E.I.T. (PEI), OrganiGram (OGI), AEterna Zentaris (AEZS) and Novan (NOVN). Who are Miragen Therapeutics' key executives? Miragen Therapeutics' management team includes the following people: Dr. William Stuart Marshall Ph.D., Co-Founder, Pres, CEO & Director (Age 55)Mr. Adam Scott Levy, Chief Bus. Officer (Age 41)Dr. Paul D. Rubin, Exec. VP of R&D (Age 65)Eric N. Olson, Co-Founder & Chairman of Scientific Advisory BoardDr. Michael R. Bristow, Co-Founder & Member of the Scientific Advisory Board (Age 74) What is Miragen Therapeutics' stock symbol? Miragen Therapeutics trades on the NASDAQ under the ticker symbol "MGEN." How do I buy shares of Miragen Therapeutics? Shares of MGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Miragen Therapeutics' stock price today? One share of MGEN stock can currently be purchased for approximately $0.83. How big of a company is Miragen Therapeutics? Miragen Therapeutics has a market capitalization of $46.99 million and generates $4.46 million in revenue each year. The medical research company earns $-41,870,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis. Miragen Therapeutics employs 77 workers across the globe. What is Miragen Therapeutics' official website? The official website for Miragen Therapeutics is www.signalgenetics.com. How can I contact Miragen Therapeutics? Miragen Therapeutics' mailing address is 6200 LOOKOUT ROAD, BOULDER CO, 80301. The medical research company can be reached via phone at 720-643-5200 or via email at [email protected] This page was last updated on 9/30/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
